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Defects in DNA mismatch repair (MMR) are associated with a predisposition to tumorigenesis and with drug resistance owing to high
mutation rates and failure to engage DNA-damage-induced apoptosis. DNA minor groove binders (MGBs) are a class of anticancer
agents highly effective in a variety of human cancers. Owing to their mode of action, DNA MGB-induced DNA damage may be a
substrate for DNA MMR. This study was aimed at investigating the effect of loss of MMR on the sensitivity to brostallicin (PNU-
166196), a novel synthetic a-bromoacrylic, second-generation DNA MGB currently in Phase II clinical trials and structurally related to
distamycin A. Brostallicin activity was compared to a benzoyl mustard derivative of distamycin A (tallimustine). We report that the
sensitivities of MLH1-deficient and -proficient HCT116 human colon carcinoma cells were comparable after treatment with
brostallicin, while tallimustine resulted in a three times lower cytotoxicity in MLH1-deficient than in -proficient cells. MSH2-deficient
HEC59 parental endometrial adenocarcinoma cells were as sensitive as the proficient HEC59þch2 cells after brostallicin treatment,
but were 1.8-fold resistant after tallimustine treatment as compared to the MSH2-proficient HEC59þch2 counterpart. In addition,
p53-deficient mouse fibroblasts lacking PMS2 were as sensitive to brostallicin as PMS2-proficient cells, but were 1.6-fold resistant to
tallimustine. Loss of neither ATM nor DNA-PK affected sensitivity to brostallicin in p53-deficient mouse embryonic fibroblasts,
indicating that brostallicin-induced cytotoxicity in a p53-deficient genetic background does not seem to require these kinases. These
data show that, unlike other DNA MGBs, MMR-deficient cells retain their sensitivity to this new a-bromoacrylic derivative, indicating
that brostallicin-induced cytotoxicity does not depend on functional DNA MMR. Since DNA MMR deficiency is common in
numerous types of tumours, brostallicin potentially offers the advantage of being effective against MMR-defective tumours that are
refractory to several anticancer agents.
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Minor groove binders (MGBs) represent an interesting class of
anticancer agents, which have been shown to be highly effective in
in vitro and in vivo preclinical tumour models unresponsive to
other antineoplastic agents (Martin et al, 1981; Li et al, 1982, 1992;
Hartley et al, 1988; D’Alessio et al, 1994; D’Incalci, 1994; Colella
et al, 1999; Marchini et al, 1999; Geroni et al, 2002). The main
representatives of this class, which reached the clinic, are the
antitumour agents derived from CC-1065, that is, adozelesin,
carzelesin, and bizelesin, and the distamycin A derivative
tallimustine. These ‘classical’ MGBs have been shown to be highly
DNA sequence-specific (Lee et al, 1993; D’Incalci, 1994) and to
exert their cytotoxic effect through the ability to per se directly
alkylate DNA mainly at the N3 position of adenines exposed in
(TA)-rich sequences in the DNA minor groove (Hurley et al, 1984;
Reynolds et al, 1985; Broggini et al, 1991, 1995; Sun and Hurley,
1992; D’Incalci, 1994; Marchini et al, 1998), without the require-
ment to be activated by other pathways (e.g., enzymatic activation
of the drug). The absence of significant antitumour activity for
nonalkylating MGBs (Marchini et al, 1998) indicates that the N3
alkylation activity of these compounds is a prerequisite for their
cytotoxicity. MGBs activity, however, has previously been reported
(Colella et al, 1999) to be associated with reduced susceptibility to
the cytotoxic effect in tumour cells with defects in DNA mismatch
repair (MMR), similar to certain chemicals, including MNNG,
which alkylates O6 of guanines, and anticancer agents such as
doxorubicin and cisplatin (Branch et al, 1995; Drummond et al,
1996).
MMR proteins recognise mismatched base pairs in the DNA,
arising either spontaneously during DNA metabolism or from
modified nucleotides provoked by physical and chemical agents,
and are thought to link DNA damage recognition to an apoptotic
pathway, thereby preventing mutagenesis, tumorigenesis, and
tumour progression (Modrich, 1991; Fink et al, 1998). Tumours
resulting from MMR-deficiency include the hereditary nonpoly-
posis colon cancer (HNPCC) and some sporadic carcinomas such
as mammary, ovarian, or endometrial cancers (Peltomaki, 2001).
The development of novel MGBs able to overcome the involvement
of MMR assumes great clinical importance with respect to the
treatment of tumours deficient in MMR. A novel a-bromoacryloyl
derivative of distamycin A, PNU-151807, which exhibits no Received 3 April 2003; revised 8 August 2003; accepted 21 August 2003
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salkylating activity per se, has been identified (Marchini et al, 1999).
The cytotoxic effect has been shown to not depend on MLH1 in
some tumour cells (Colella et al, 1999) and has been attributed to
the a-bromoacrylic moiety of the compound, which seems to
interfere with cell cycle progression via yet unknown pathways
(Cozzi, 2000; Geroni et al, 2002).
Recently, brostallicin (PNU-166196), a synthetic a-bromoacrylic
MGB structurally related to PNU-151807, has been selected for
clinical development. Brostallicin has shown very promising
activity in experimental tumour models; its in vitro and in vivo
activity is increased in tumour cells with higher glutathione (GSH)
and/or glutathione-S-transferase (GST) levels (Geroni et al, 2002).
The a-bromoacrylic moiety of brostallicin was found to react with
GSH, in a reaction catalysed by GST, with the possible formation of
a highly reactive GSH-complex able to bind covalently to DNA
(Geroni et al, 2002; Cozzi, 2003).
The present study was aimed at investigating the effect of loss of
MMR on the sensitivity to brostallicin compared to the structurally
related tallimustine, using cell lines deficient or proficient in
MLH1, MSH2, or PMS2, respectively. A putative involvement of
two members of the PI3-like kinase family, ATM and DNA-PK,
which link DNA damage and cell cycle response in drug-induced
cytotoxicity, was also investigated. We report that MMR-deficient
cells retain sensitivity to brostallicin, thereby extending the list of
potential anticancer agents for use in the treatment of MMR-
deficient tumours, and that brostallicin-induced cytotoxicity may
not require ATM and DNA-PK.
MATERIALS AND METHODS
Cell lines
The MLH1-deficient human colorectal adenocarcinoma cell line
HCT116 was obtained from the American Type Culture Collection
(ATCC CCL 247), and a subline complemented with chromosome 3
carrying the wild-type gene for hMLH1 (clone HCT116/3–6,
identified here as HCT116þch3) was obtained from Dr M Koi
(Koi et al, 1994) as were the MSH2-deficient human endometrial
adenocarcinoma cell line HEC59 (Umar et al, 1997) and a subline
complemented with chromosome 2 carrying the wild-type gene for
hMSH2 (clone HEC59/2–4, identified here as HEC59þch2).
HCT116 cells contain a hemizygous mutation in MLH1 resulting
in a truncated, nonfunctional protein (Boyer et al, 1995). Similarly,
the HEC59 cells are mutated at different loci on both alleles of
MSH2 and are deficient in repair activity (Umar et al, 1997). The
chromosome-complemented sublines HCT116þch3 and
HEC59þch2 are competent in DNA MMR. HCT116 and HEC59
cell lines were maintained in Iscove’s modified Dulbecco’s medium
(Life Technologies, Basel, Switzerland) supplemented with 2mML -
glutamine and 10% heat-inactivated foetal bovine serum (Oxoid,
Basel, Switzerland). The chromosome-complemented lines were
maintained in a medium supplemented with geneticin (400mgml
 1
for HCT116þch3, and 600mgml
 1 for HEC59þch2) (Life
Technologies). Although the extent of possible effects of the
introduction of an extra chromosome are not fully clear, it is
generally acknowledged that it does not spoil the effects of loss of
MMR on drug sensitivity. PMS2
 / /p53
 /  and PMS2
þ/þ/p53
 / 
cell lines, established from E1A/Ha-Ras-transformed knockout
mice primary fibroblasts, were generously provided by Dr P Glazer
(Zeng et al, 2000). Cells are maintained in culture for a limited
number of passages and are routinely tested for the expression of
MMR proteins. The ATM
þ/þ/p53
 /  and ATM
 / /p53
 / , and
the DNA-PK
þ/þ/p53
 /  and DNA-PK
 / /p53
 /  mouse embryo-
nic fibroblasts, were generously provided by Dr P Leder (Westphal
et al, 1997) and Dr EH Goodwin (Bailey et al, 1999), respectively.
The cells were maintained in DMEM medium supplemented with
2m ML -glutamine (Life Technologies), 10% heat-inactivated foetal
calf serum (Oxoid) and penicillin/streptomycin (100Uml
 1/
100mgml
 1, Life Technologies). All cell lines were tested negative
for contamination with Mycoplasma spp. and maintained in a
controlled environment of 5% CO2 and 95% relative humidity at
371C. Except for the ATM
þ/þ/p53
 /  and ATM
 / /p53
 /  mouse
cells, which grow as a monolayer and do not form colonies, all
other cell lines used in these experiments form well-defined
individual colonies when seeded sparsely on standard tissue
culture plates.
Reagents
Distamycin A and its derivatives brostallicin (PNU-166196) and
tallimustine (PNU-152241) were synthesised by Pharmacia Italy
(Nerviano, Italy). The chemical structures of the derivatives are
presented in Figure 1. Brostallicin was dissolved in methanol,
tallimustine in DMSO, and distamycin A in water. Stock solutions
were stored at  201C. The final concentration of DMSO or
methanol in the cultures was o0.1% at all drug concentrations
and in controls. Previous experiments (data not shown) have
shown that neither 0.1% DMSO nor 0.1% methanol affects the
viability or growth of these cell lines.
MPE footprinting analysis
The MPE footprinting method has been previously described in
detail (Hertzberg and Dervan, 1984). The 4492- and 751-bp
fragments of SV40-labelled plasmid previously described (March-
ini et al, 1999) were incubated with distamycin A, tallimustine, and
brostalicin (50mM) for 1h at room temperature and treated for
30min at room temperature with a solution of MPE-(NH4)2-
Fe(SO4)2 (synthesised by Pharmacia, Italy, according to the
published method; Hertzberg and Dervan, 1984). After precipita-
tion, DNA was resuspended in loading buffer and electrophoresed
on an 8% polyacrylamide 7 M urea gel and autoradiographed.
Taq polymerase stop assay
Studies with the Taq stop assay were based on a previously
reported method (Ponti et al, 1991). Prior to drug-DNA
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Figure 1 Chemical structures of brostallicin and tallimustine. Both
molecules share the distamycin A backbone.
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sincubation, plasmid pBSSK-TOPO II was linearised with a PstI
restriction enzyme (NEB) to provide a stop for the Taq
polymerase, downstream from the primer. After drug treatment,
the DNA was precipitated and washed as described (Ponti et al,
1991). The primer was 50-end labelled with T4 polynucleotide
kinase (NEB) and [g-
32P] ATP (5000Cimmol
 1, Amersham). The
synthetic primer sequence and the linear PCR amplification
conditions were performed as described (Marchini et al, 1998).
Samples were then purified by extraction with an equal volume of
chloroform–isoamyl alcohol (24:1), and then precipitated and
washed following the standard protocol. Dried samples were
resuspended in loading buffer and denatured at 901C for 2min
before loading onto an 8% polyacrylamide denatured gel. After the
run, the gel was dried and autoradiographed.
Clonogenic survival and MTT proliferation assays
Clonogenic survival in response to drug treatment was performed
by plating 250 cells in 60mm cell culture dishes. After 24h, the
drug was added, followed by incubation in a drug-containing
medium for 2h or 24h and then in a drug-free medium for another
6–8 days at 371C in a humidified atmosphere containing 5%
carbon dioxide. Cells were then fixed with 25% acetic acid in
ethanol and stained with Giemsa. Colonies of at least 50 cells were
scored visually. Each experiment was performed a minimum of
three times using triplicate cultures for each drug concentration.
The logarithm of relative colony formation was plotted against the
concentration of the drug. The IC50 was estimated by linear
interpolation of the logarithmic transformed relative plating
efficiencies.
For ATM
þ/þ/p53
 /  and ATM
 / /p53
 /  mouse cells that do
not form distinct colonies, the drug sensitivity was determined by
the MTT assay (Mosmann, 1983). MTT (3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazoliumbromide) measures the mi-
tochondrial dehydrogenase of surviving cells. Cells growing in the
log phase were harvested by brief trypsinisation. A total of 1000
cells were plated (96 well plates) 24h prior to 2h drug treatment.
Cells were then grown in a drug-free medium for another 4 days at
371C in a humidified atmosphere containing 5% carbon dioxide. A
volume of 20ml MTT in PBS to a final concentration of 0.5mgml
 1
was added, followed by incubation at 371C for 4h, aspiration of the
medium, and addition of 200ml DMSO. The optical density was
measured by the Emax microplate reader E9336 (Molecular Devices,
Clearwater, MN, USA) at 540nm, setting the value of the cell lines
in the medium to 1.0 (control) and the value of the no cells blank
to zero. Differences in drug sensitivity of the respective cell lines
were determined from at least four independent experiments and
are reported as the concentration required to suppress prolifera-
tion by 50% (IC50).
Statistical analysis
The mean7s.d. values were calculated for all data sets. The two-
sided paired t-test was used to compare the effects on drug
sensitivity. Po0.05 was considered to be statistically significant.
RESULTS
Brostallicin does not alkylate DNA per se but through the
interaction with GSH/GST
Noncovalent interactions of brostallicin and tallimustine (TAM)
with DNA were compared to those of distamycin A (DISTA). The
data reported in Figure 2 show an autoradiograph of a classical
ladder of an MPE-footprinting experiment tested on the 751-bp
(panel A) and 4492-bp fragments (panel B) of the SV40 DNA
plasmid. Each band corresponds to a DNA fragment differing in
size by a single nucleotide. When a DNA region is protected by the
presence of a molecule, chemical digestion is blocked and a ‘gap’ is
present on the autoradiograph. In the control (CTR, Figure 2), all
fragments are present with broadly the same signal intensity on the
gel, while in all the treated sample lanes a typical ‘gap’ is common
in AT-rich regions. The brackets highlight these regions. The
distamycin A backbone present in the brostallicin chemical
structure drives the DNA interaction towards AT-rich regions in
the same way as previously shown for tallimustine. In fact,
brostallicin shows a noncovalent DNA interaction effect super-
imposable to that of tallimustine and distamycin A (internal
positive control). These regions are highlighted by brackets. The
differences in band intensities were due to differences in gel
loading.
On the basis of the previously reported data showing that
brostallicin is able to covalently interact with DNA upon in vitro
reduction by the GSH/GST system (Geroni et al, 2002), we further
tested this hypothesis by incubating the drug-DNA solution with
and without GSH and GST in an in vitro system. The sequence-
specific, covalent DNA interaction of brostallicin in comparison
with tallimustine was analysed by the Taq polymerase stop assay.
This assay is a linear amplification method employing the
C
T
R
D
S
T
T
A
M
B
R
O
T
S
T
A
L
L
I
C
I
N
C
T
R
D
S
T
T
A
M
B
R
O
T
S
T
A
L
L
I
C
I
N
AB
Figure 2 MPE footprinting analysis of the SV40 DNA plasmid (751-bp,
panel A; and 4492-bp, panel B) treated with distamycin A (DISTA),
tallimustine (TAM), and brostallicin as described in Materials and Methods
section. CTR¼untreated control DNA. Brackets on the right-hand side of
the picture refer to AT-rich regions determined by DNA sequencing.
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sproperties of DNA polymerase to investigate the sequence
selectivity of the interaction between DNA-damaging agents and
the DNA. As expected, tallimustine retained its high sequence
specificity in alkylating DNA at the target hexamer (50-TTTTGA),
while brostallicin per se was completely unable to produce any
alkylation in the selected DNA region (Figure 3). Brostallicin alone
did not alkylate DNA, while a band was observed when GST/GSH
was added to the reaction mixture. In the absence of brostallicin,
GSH/GST did not induce any alteration able to block Taq
polymerase. It is important to underline the fact that, although
the interaction of brostallicin with DNA involves AT-rich regions,
the compound binds to a sequence (AAAG) different from those
previously reported for tallimustine. Studies are still in progress to
better define the sequence of the alkylated regions.
Loss of MLH1 or MSH2 does not alter sensitivity to
brostallicin
The question was addressed as to whether loss of either MLH1 or
MSH2 affects the sensitivity to brostallicin using the clonogenic
assay. The data presented in Table 1 show that MLH1-deficient
HCT116 cells are nearly as sensitive as MLH1-proficient
HCT116þch3 cells to this drug (P¼0.36). This indicates that
MLH1 is not involved in brostallicin-mediated cytotoxicity.
Furthermore, MSH2-deficient HEC59 cells are as sensitive to
brostallicin as MSH2-proficient HEC59þch2 cells (P¼0.41),
indicating that brostallicin-mediated cytotoxicity does not require
functional MSH2. Brostallicin cytotoxiciy has been compared to
tallimustine. The results show that MLH1-deficient and MSH2-
deficient cells are three-fold (Po0.01) and 1.8-fold (P¼0.03),
respectively, less sensitive to tallimustine than their respective
proficient counterparts.
Sensitivity to brostallicin, but not to tallimustine, is
retained after loss of PMS2
Although less frequently mutated than MLH1 or MSH2 in human
cancers, PMS2 may nevertheless be relevant in this respect since it
forms a heterodimer with MLH1 and the lack of one or the other
partner affects MMR activity. Based on the model that cytotoxicity
of tallimustine, but not the a-bromoacrylic derivatives, is
dependent on functional MMR, it is anticipated that loss of
PMS2 negatively affects sensitivity to tallimustine, but not to
brostallicin. The effect of loss of PMS2 on drug sensitivity was
investigated in p53-deficient cells derived from knockout mice.
Table 2 shows that the clonogenic survival after treatment with
brostallicin in PMS2-deficient cells was not different from that in
PMS2-proficient cells (P¼0.79). In contrast, PMS2-deficient cells
were 1.6-fold less sensitive to tallimustine than PMS2-proficient
cells (P¼0.02).
Thus, PMS2-deficient p53-null mouse fibroblasts retain sensi-
tivity to brostallicin. The 1.6-fold resistance to tallimustine in
PMS2-deficient cells indicates a role for PMS2 in sensitivity to this
compound.
Loss of ATM or DNA-PK does not affect sensitivity to
brostallicin
It has previously been proposed that the cytotoxic effect of the a-
bromoacrylic derivative PNU-151807 interferes with the cell cycle
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Figure 3 Autoradiography of a typical Taq Stop Assay on topoisome-
rase II cDNA after treatment with brostallicin and tallimustine (TAM). The
experiment was performed as described in Materials and Methods section.
CTR¼control untreated sample. Arrows indicate the alkylated regions.
Table 1 IC50 concentrations for clonogenic survival of MMR-proficient
or -deficient cells in response to treatment with brostallicin or tallimustine
Compound Cell line IC50 (nM) Ratio
a P
b
Brostallicin HCT116+ch3 13.173.2
HCT116par 14.972.8 1.14 0.36
HEC59+ch2 28.774.5
HEC59par 35.079.9 1.22 0.41
Tallimustine HCT116+ch3 44.373.9
HCT116par 133.576.4 3.06 o0.01
HEC59+ch2 13.172.6
HEC59par 24.074.6 1.83 0.03
Mean7s.d. of at least three independent data sets.
aRatio of IC50 values of MMR-
deficient cells and -proficient cells.
bTwo-sided paired t-test.
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scheckpoint control (Marchini et al, 1999). Although yet unknown,
a possible pathway may include ATM or DNA-PK, members of the
PI3-like kinase family, which are important kinases for connecting
DNA damage monitoring and cellular responses such as cell cycle
checkpoint activation and apoptosis. The question was addressed
as to whether the sensitivity to brostallicin is affected by loss of
ATM or DNA-PK in a p53-deficient genetic background. We used
embryonic fibroblasts from knockout mice. The data presented in
Figure 4 show that ATM-deficient cells (0.870.3mM) were as
sensitive to brostallicin as ATM-proficient cells (0.970.2mM)i na
p53-deficient genetic setting (P¼0.60). Likewise, DNA-PK-defi-
cient cells (17.570.7nM) were as sensitive to brostallicin as DNA-
PK-proficient cells (21.071.4nM) in a p53-null background
(P¼0.13).
Thus, neither ATM nor DNA-PK seems to be involved in the
sensitivity to brostallicin in p53-deficient mouse cells.
DISCUSSION
The present study demonstrates that brostallicin, a novel a-
bromoacrylic, second-generation DNA MGB structurally related to
distamycin A, maintains its cytotoxic effect in cells deficient for the
MMR proteins MLH1, MSH2, or PMS2. The data permit drawing
several conclusions. First, brostallicin, the lead compound of a
novel class of MGBs in clinical trials, exerts its cytotoxic effect
regardless of the MMR status, suggesting that further clinical
testing of brostallicin in tumours deficient in MMR is to be
recommended. Second, brostallicin-induced cytotoxicity can occur
in the absence of functional ATM or DNA-PK in p53-deficient
cells, indicating that brostallicin-induced cytotoxicity in this
setting is independent of PI3-like kinase family status. Third,
brostallicin is the first MGB unable to per se covalently interact
with DNA. It requires the GSH/GST system to alkylate DNA with a
sequence specificity different from that reported for previously
tested alkylating molecules.
MMR plays an important role in the correction of spontaneously
occurring errors during DNA processing that have escaped the
DNA polymerase proof-reading activity, thereby preserving the
integrity of the genome by preventing the occurrence of gene
mutations and tumorigenesis (Modrich, 1991). Spontaneous
tumours arising from MMR deficiency include the hereditary
nonpolyposis colon cancer as well as some sporadic carcinomas
such as mammary, ovarian, or endometrial cancers (Peltomaki,
2001). MMR monitors specific types of DNA damage introduced
by DNA-damaging agents, and subsequently triggers an apoptotic
response (Fink et al, 1998). Loss of MMR hence results in
resistance to a variety of widely used anticancer drugs, including
the topoisomerase I poisons camptothecin and topotecan, the
topoisomerase II poisons doxorubicin, epirubicin, mitoxantrone
and etoposide, and some platinum compounds such as cisplatin
and carboplatin, as well as some alkylating agents including
MNNG and busulphan (Branch et al, 1995; Drummond et al, 1996;
Fink et al, 1996, 1998; Fedier et al, 2001).
Interestingly, the MMR status also affects the activity of several
MGBs such as CC-1065 analogues and the distamycin-derivative
tallimustine, but not that of the a-bromoacryoyl derivative of
distamycin A (PNU-151807) (Colella et al, 1999). The present study
expands on this previous finding by demonstrating that brostalli-
cin, a novel second-generation DNA MGB structurally related to
PNU-151807, exerts its cytotoxic effect regardless of the MMR
status. Brostallicin as well as the class of the taxanes (Fedier et al,
2001) and photodynamic therapy (Schwarz et al, 2002) may thus
represent valuable options for the treatment of tumours disabled
in MMR.
The a-bromoacryoyl moiety has been proposed to be important
since it reacts with GSH, and reactive drug-GSH intermediates may
then modify the DNA by mechanisms not yet fully understood
(Geroni et al, 2002; Cozzi, 2003). DNA interaction data reported in
the present study suggest that the distamycin A backbone drives
the brostallicin molecule towards the AT regions present in the
minor groove of the DNA. In addition, brostallicin binds
covalently to DNA through interaction with the GSH/GST system.
Brostallicin covalently binds to DNA with a completely different
sequence specificity than tallimustine. One hypothesis for the
different behaviour of brostallicin against MMR status is that this
covalent interaction is not substrate for MMR, whereas the
alkylated DNA by tallimustine is recognised by MMR. It should
be noted that no direct interaction between MMR and the GSH/
GST system is known, and that the GSH/GST status of the cell lines
Table 2 IC50 concentrations for clonogenic survival of PMS2-proficient
or -deficient mouse cells in a p53-deficient genetic setting in response to
drug treatment
Drug PMS2
+/+/p53
 /  PMS2
 / /p53
 /  Ratio
a P
b
Brostallicin (nM) 27.372.8 26.376.7 0.96 0.79
Tallimustine (nM) 139719 223742 1.60 0.02
Mean7s.d. of at least three independent data sets.
aRatio of IC50 values of MMR-
deficient cells and -proficient cells.
bTwo-sided paired t-test.
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Figure 4 Sensitivity to brostallicin of ATM
 / /p53
 /  (&) and ATM
þ/
þ/p53
 /  (’) mouse cells determined by the MTT assay (A) and of
DNA-PK
 / /p53
 /  (J) and DNA-PK
þ/þ/p53
 /  (K) mouse cells
determined by the clonogenic assay (B), expressed as the percentage of
the untreated controls. Each point represents the mean7s.d. of at least
four independent experiments.
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sunder study does not matter for the experiments because the cell
lines are quasi-isogenic, that is, they differ only in their MMR
status and the extra chromosomes.
Moreover, as reported for PNU-151807, the bromoacryloyl
moiety seems to be relevant for cell cycle checkpoint control
(Marchini et al, 1999). The identity of mediators for signalling
between DNA damage and downstream effectors is not clear. One
possibility is that the DNA damage is recognised by one or several
members of BASC (BRCA1-associated genome surveillance com-
plex), a multiprotein complex including BRCA1, ATM, MMR
proteins, and other proteins implicated in DNA repair (Wang et al,
2000). Our data, however, show that deficiency in ATM or DNA-
PK did not affect brostallicin sensitivity in p53-deficient cells,
arguing against a role of these kinases in these cells. Since these
kinases are activated upon DNA double-strand breaks introduced
by radiation or radiomimetic drugs (Jackson, 1997; Smith et al,
1999), a-bromoacryoyl derivatives seem unlikely to produce this
type of lesion. Although the cytotoxic effect of tallimustine and
PNU-151807 has been shown not to be dependent on the p53 status
(Marchini et al, 1999), the data for these kinases obtained in p53-
deficient cells may not be conclusive for p53-proficient cells. There
is an apparent higher sensitivity to brostallicin of the DNA-PK data
set compared to the ATM data set, but this is likely due to the use
of two assays that differ in their sensitivities.
Mutations in the p53 tumour suppressor gene are found in a
large fraction of human cancers (Hollstein et al, 1991) and this
may be the genetic basis underlying failure to respond to
chemotherapy (Ferreira et al, 1999). PNU-151807 has recently
been reported to retain sensitivity against cells disabled in p53
function (Marchini et al, 1999), indicating that PNU-151807-
mediated cytotoxicity does not require functional p53. We have
recently shown that additional loss of PMS2 in p53-deficient cells
increases cytotoxicity to a variety of anticancer agents (Fedier et al,
2002). This hypersensitising effect, however, was not observed in
response to treatment with brostallicin. For tallimustine, even an
opposite effect was observed in PMS2-deficient cells, suggesting
that tallimustine-induced DNA damage is a substrate for MMR in
p53-deficient cells. Consistent with this, tallimustine-induced DNA
damage has already been shown to be a substrate for MMR in p53-
proficient cells (Colella et al, 1999).
We also observed that tallimustine is less toxic than brostallicin
in p53-deficient cells and that this effect is much greater than the
difference in sensitivity to tallimustine between MMR-deficient
and -proficient cells. This marked effect was not observed in p53-
proficient cells. As the status of p53 has been reported not to
markedly affect the sensitivity of human tumour cells to either
tallimustine or PNU-151807 (Marchini et al, 1998), this effect in
p53-deficient cells may be ascribed to the mouse origin and/or to
the fibroblast cell type.
In summary, the present study demonstrates that brostallicin-
mediated cytotoxicity does not depend on the MMR status of
tumour cells, and that, at least in p53-deficient mouse cells,
functional ATM or DNA-PK is not required. Brostallicin poten-
tially offers the advantage of having efficacy on MMR-defective
tumours that are refractory to several anticancer agents. Since the
responsiveness to cisplatin treatment is affected by both MMR
status and GSH/GST level/expression, brostallicin is a good
candidate for clinical protocols.
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